Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

AX immunotherapy for prostate cancer in its bioreactor manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product during commercialization.

Conference Call and Webcast

Members of the Cell Genesys management team will host a conference call today, Monday, January 14 at 10:00 a.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, http://www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the United States and 320-365-3844 from outside the United States. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 907247.

About Cell Genesys

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results, analysis
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Medical, Inc. (Nasdaq: NXTM ), a leading ... a group of its home hemodialysis patients and ... conventional (non-dialysis) Caribbean cruise with their NxStage® System ... Freedom Cruise: We,re Taking Home Dialysis to Sea," ... and returns on January 10, 2010. The ...
(Date:12/15/2009)... Dec. 15 Vivakor, Inc. (OTC ... divisions have reported strong performance in 2009. ... and development with divisional spokes developing multiple ... Product Pipeline strategy is anchored to the ... idea inception, Vivakor,s R&D efforts target commercialization ...
(Date:12/15/2009)... NEW HAVEN, Conn., Dec. 15 Rib-X ... development and commercialization of novel drugs for the ... has entered into a collaborative research agreement with ... the science plan for the collaboration, Dr. David ... delafloxacin, in an established animal model to determine ...
Breaking Medicine Technology:Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Vivakor Divisions Continue to Demonstrate Independent Growth 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Teenage obesity linked to increased risk of MS 10670 1Teenage obesity linked to increased risk of MS 10670 2Launching StaffingClub com a New Online Networking Platform for Recruiting and Staffing Professionals 61016 1Launching StaffingClub com a New Online Networking Platform for Recruiting and Staffing Professionals 61016 2Handwriting Skills May Lag in Kids With Autism 61014 1Handwriting Skills May Lag in Kids With Autism 61014 2
... Entrance into the Injectable Filler Market, PALO ALTO, ... launch of its Novielle Voice family of injectable fillers ... Otolaryngology -- Head,and Neck Surgery (AAO-HNS) in Chicago, IL, ... Administration (FDA) cleared Novielle Voice Gel,and Novielle Voice GelPlus ...
... Sept. 19 Enobia Pharma, an emerging biotech,company ... announced that it has received Orphan Drug designation ... ENB-0040, its enzyme,replacement therapy (ERT) for hypophosphatasia, a ... dosed the first patient in a,Phase I clinical ...
Other Medicine Technology:Coapt Systems Launches FDA Cleared Novielle Voice (TM) for Restoration of Voice Loss 2Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040 2Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040 3
(Date:12/15/2009)... American Diabetes Association and the CDC have released some sobering statistics ... United States. Treadmill desks offer employers an effective means of combating ... ... (Vocus) December 14, 2009 -- Rates of diabetes are climbing across ... obesity rates. Despite this rise the American Diabetes Association has stated ...
(Date:12/15/2009)... advocates to be leaders in the fight against ... from experts in online learning, the Masie Center ... ONE and Malaria No ... the first-ever "Malaria Griots" program, a dynamic education ... become leaders in the fight against malaria. ...
(Date:12/15/2009)... 4R Systems, Inc., a leading provider ... help retailers significantly increase profits by optimizing their ... that The Vitamin Shoppe has been utilizing the ... and DC inventory solutions have helped us drive ... over the last two years," said Tony Truesdale, ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will be cautioning ... matter whether there,s a public option. The current Senate ... give government authority over how your doctor treats you. ... by shifting billions of dollars from Medicare to handouts ... politicians." ,, Betsy McCaughey is the Founder/Chairman ...
(Date:12/15/2009)... 15 The new compact LifeSpan TR200 folding ... www.LifeSpanFitness.com ), was highly praised by treadmill review ... 2010. The compact TR200 folding treadmill received awards for ... under $1000. ,, The compact LifeSpan TR200 treadmill ... workout spaces. "This category buster is a very compact ...
Breaking Medicine News(10 mins):Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2
... 3 Prime Healthcare Services,Inc. (PHS) entered into a ... February 28, 2008 for all of their products,i.e., PPO, ... at any one of,PHS, hospitals* for outpatient and inpatient ... Aetna enrollees will be covered,with full in-network benefits., ...
... March 3 Aircraft Medical, the UK,medical devices ... the,prestigious 14th World Congress of Anaesthesiologists (the "Congress" ... Held every four,years, the WCA is the foremost ... Aircraft Medical sponsoring the event, but the company,s,McGRATH(R) ...
... AIDS Vaccine Initiative (IAVI) today announced the first award ... will identify and advance potential breakthrough technologies and apply ... project will apply an exciting new technology, a simulated ... which has the potential to predict human immune responses ...
... City, black babies with very low birth weights (less than ... to be born in hospitals with high risk-adjusted neonatal death ... issue of Pediatrics. White very low birth weight (VLBW) babies ... risk-adjusted neonatal death rates. In fact, only 11 percent of ...
... Eisai Corporation of,North America, its U.S. subsidiary, ... that the U.S. Food and Drug Administration,(FDA) has ... postoperative nausea and vomiting (PONV) for up to ... not been demonstrated., Aloxi, available in the ...
... ANGELES, March 2, 2008 Researchers at the University ... to develop more effective tumor vaccines by turning off ... of the study, titled A20 is an antigen presentation ... will be published in Nature Medicine on March 2, ...
Other Medicine News:Health News:Prime Healthcare Services Enters Into Network Wide Contract With Aetna Health Plans 2Health News:Aircraft Medical to Sponsor World's Premier Anaesthesiology Conference 2Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Black VLBW babies in NYC more likely to be born in hospitals with high neonatal death rates 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 3Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 4Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 5Health News:USC researchers discover novel way to develop tumor vaccines 2
... includes fixed-volume, adjustable-volume, and multichannel models ... Research pro Pipette. Designed with a ... pipettes have earned a worldwide reputation ... with original Eppendorf pipette tips, they ...
50L...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: